PHILADELPHIA and VANCOUVER, British Columbia and BOSTON — November 20, 2025 — Leads & Copy — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) announced that its subsidiary, BriaPro Therapeutics Corp., has initiated a research collaboration with Receptor.AI to design anti-cancer isoform-selective kinase inhibitors for multiple cancer indications.
The collaboration integrates AI-driven molecular design expertise with BriaPro’s proprietary technology to expand BriaPro’s small-molecule pipeline. The goal is to accelerate the development of selective kinase inhibitors that may enhance immune-mediated tumor targeting and improve cancer patient outcomes.
Dr. William V. Williams, President and CEO of BriaCell and BriaPro, stated that the partnership marks an important step in BriaCell’s strategic expansion beyond cell-based immunotherapy into small-molecule discovery, reinforcing its mission to deliver differentiated and complementary approaches to cancer treatment.
Dr. Alan Nafiev, CEO and Founder of Receptor.AI, said that kinase selectivity, down to the isoform level, remains one of the hardest optimization problems in oncology. He added that the collaboration is about bringing disciplined, AI-first molecular design and rigorous ADMET constraints to BriaCell’s oncology programs, enhancing precision and translational confidence from the earliest stages of discovery.
Receptor.AI will use its small-molecule discovery platform to drive target assessment, hit identification, and lead optimization, with a particular focus on achieving precise isoform selectivity among closely related kinases.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, according to the release. BriaPro Therapeutics Corp. is a pre-clinical stage immunotherapy company developing binding agents and proteins designed to enhance the ability of the body’s own cancer-fighting cells to eliminate tumors. BriaPro is a wholly owned subsidiary of BriaCell Therapeutics Corp.
Receptor.AI, a next-generation TechBio company transforming drug discovery through AI-native infrastructure and deep modality expertise, integrates machine learning, physics-based modeling, and automated decision-making into a unified R&D platform, according to the release.
With a track record across more than 40 discovery programs, Receptor.AI drives innovation across small molecules, peptides, and induced-proximity therapeutics, partnering with global biopharma and academic institutions to unlock challenging targets and accelerate the path from concept to clinic.
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations
investors@briacell.com
Source: BriaCell Therapeutics Corp.
Source: BriaCell Therapeutics Corp.
